PDF TOP10 (Weighting Descending%)
Eli Lilly & Co
24.86%Novo Nordisk A/S
23.36%Merck & Co Inc
11.62%AstraZeneca PLC
8.21%Novartis AG
7.21%Roche Holding AG
7.12%Amgen Inc
5.67%Pfizer Inc
5.52%Regeneron Pharmaceuticals Inc
3.74%Chugai Pharmaceutical Co Ltd
1.92%Related document
| Fund Name | TIGER GLOBAL OBESITY TREATMENT TOP 2 Plus ETF |
|---|---|
| Legal Structure | Domestic Investment Trust , Open-end |
| Benchmark Index | Indxx Global Obesity Treatment Top 2 Plus 지수(Price Reutrn) |
| Total Expense Ratio | 0.45% |
| Dividend |
| Manager | Mirae Asset Global Investments |
|---|---|
| Trustee | HSBC |
| Investment Methodology | Full Replication or Optimization |
| Stock Exchange | |
|---|---|
| Stock Code | 476690 |
| Bloomberg | 476690 KS |
| Currency Denomination | Korean Won |
| Index Multiplier | 1X |
| Pricing | 10,000 Won |
| Board Lot | 1 share |
| Creation Unit | 50,000 Shares |
| First Trading Date | 2024-02-29 |
| Authorized Participants | KB Securities ,Meritz Securities ,Mirae Asset Securities ,Samsung Securities ,Shinhan Securities ,eBEST Investment & Securities ,Kiwoom Securities ,Korea Investment & Securities |
| Liquidity Providers | Meritz Securities ,Mirae Asset Securities ,eBEST Investment & Securities ,Kiwoom Securities ,Korea Investment & Securities |
| Transaction Tax | Exempted |
| Short Selling | Allowed and exempted from up-tick rule |
| IOPV Calculation | Every 10 seconds, disclosed on the KRX website |
| TIGER website | www.tigeretf.com |
| KRW website |